OneSource Specialty Pharma Ltd's Q3FY25 Quarter Results
- 30 Jan 2025
Result Summary
- OneSource Specialty Pharma Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were - by - QoQ and - - YoY.
- The net profit - - QoQ and - - YoY.
- The earnings per share (EPS) of OneSource Specialty Pharma Ltd declined at 6.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 397.96 | 0.00 | 0.00 | - | - |
Total Expenses | 363.93 | 0.00 | 0.00 | - | - |
Profit Before Tax | -66.50 | - | - | NaN% | NaN% |
Tax | 2.35 | 0.00 | 0.00 | - | - |
Profit After Tax | -68.85 | 0.00 | 0.00 | - | - |
Earnings Per Share | -6.30 | 0.00 | 0.00 | - | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
OneSource Specialty Pharma Ltd is a company engaged in the pharmaceutical industry, focusing on the development and distribution of specialized pharmaceutical products. As of the latest available data, the company is known for its innovative approach to addressing niche therapeutic areas with unmet medical needs. While specific details about its main products or recent developments are not provided, OneSource Specialty Pharma Ltd is typically involved in formulating drugs that cater to specialized segments, possibly including rare diseases or personalized medicine. The company aims to leverage its expertise in pharmaceutical sciences to enhance patient outcomes and improve healthcare solutions.
Revenue
During the third quarter of the fiscal year 2025 (Q3FY25), OneSource Specialty Pharma Ltd reported a total income of ₹397.96 crores. This figure represents the entirety of the company's revenue streams, encompassing sales, services, and other income sources within the specified period. The data for the previous quarter (Q2FY25) and the corresponding quarter of the previous year (Q3FY24) are not available, thus YoY and QoQ comparisons cannot be established. The absence of these figures limits the ability to analyze revenue trends over time. Therefore, the focus remains solely on the absolute revenue figure reported for Q3FY25, which is crucial for understanding the company's financial scope in the recent quarter.
Profitability
In terms of profitability, OneSource Specialty Pharma Ltd recorded a Profit Before Tax (PBT) of -₹66.50 crores for Q3FY25. After accounting for taxes amounting to ₹2.35 crores, the company reported a Profit After Tax (PAT) of -₹68.85 crores. These figures indicate the company's performance in terms of earnings before and after tax deductions within the quarter. Earnings Per Share (EPS) for the same period stood at -₹6.30. The lack of comparative data for previous quarters (Q2FY25 and Q3FY24) precludes any effective analysis of profitability trends over time. The figures underscore the company's financial performance in the current quarter, focusing on the reported losses both before and after tax adjustments.
Operating Metrics
The operating metrics for OneSource Specialty Pharma Ltd, as provided, highlight the total expenses incurred during Q3FY25, which amounted to ₹363.93 crores. This reflects the cost structure of the company in terms of operational expenditures within the quarter. Without data from previous quarters (Q2FY25 and Q3FY24), it is challenging to assess the efficiency or cost management trends over time. The available data emphasizes the company's expenditure relative to its income within the quarter, providing a snapshot of operational financial dynamics. The absence of detailed financial ratios or additional operational metrics limits further insights into liquidity, solvency, or operational efficiency.
